103 related articles for article (PubMed ID: 19523815)
1. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Thomas F; Rochaix P; White-Koning M; Hennebelle I; Sarini J; Benlyazid A; Malard L; Lefebvre JL; Chatelut E; Delord JP
Eur J Cancer; 2009 Sep; 45(13):2316-23. PubMed ID: 19523815
[TBL] [Abstract][Full Text] [Related]
2. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
White-Koning M; Civade E; Geoerger B; Thomas F; Le Deley MC; Hennebelle I; Delord JP; Chatelut E; Vassal G
Clin Cancer Res; 2011 Jul; 17(14):4862-71. PubMed ID: 21653689
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.
Thomas F; Rochaix P; Benlyazid A; Sarini J; Rives M; Lefebvre JL; Allal BC; Courbon F; Chatelut E; Delord JP
Clin Cancer Res; 2007 Dec; 13(23):7086-92. PubMed ID: 18056187
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
7. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
[TBL] [Abstract][Full Text] [Related]
9. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Kraut EH; Rhoades C; Zhang Y; Cheng H; Aimiumu J; Chen P; Lang J; Young DC; Agrawal A; Dancey J; Chan KK; Grever MR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):579-86. PubMed ID: 20490801
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Pander J; Guchelaar HJ; Gelderblom H
Curr Opin Mol Ther; 2010 Dec; 12(6):654-61. PubMed ID: 21154157
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
14. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
15. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E; Buclin T; Guidi M; Quoix E; Gourieux B; Decosterd LA; Gairard-Dory AC; Ubeaud-Séquier G; Widmer N
Ther Drug Monit; 2015 Feb; 37(1):2-21. PubMed ID: 24831652
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Liu G; Cheng D; Ding K; Le Maitre A; Liu N; Patel D; Chen Z; Seymour L; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Feb; 7(2):316-22. PubMed ID: 22237259
[TBL] [Abstract][Full Text] [Related]
19. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Mizuno T; Fukudo M; Fukuda T; Terada T; Dong M; Kamba T; Yamasaki T; Ogawa O; Katsura T; Inui K; Vinks AA; Matsubara K
Ther Drug Monit; 2014 Jun; 36(3):310-6. PubMed ID: 24825438
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.
Thomas F; Delmar P; Vergez S; Rochaix P; Hennebelle I; McLoughlin P; Benlyazid A; Sarini J; Delord JP
Head Neck; 2013 Jun; 35(6):809-18. PubMed ID: 22791662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
